Drug Mechanism Enrichment Analysis: A tool to link molecular signatures with sensitivity to drug mechanisms of action

[1]  U. Sauer,et al.  High‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins , 2022, Molecular systems biology.

[2]  A. Haslam,et al.  Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Wenyu Lin,et al.  SLC7A11/xCT in cancer: biological functions and therapeutic implications. , 2020, American journal of cancer research.

[4]  L. Zhuang,et al.  Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy , 2020, Protein & Cell.

[5]  Sanghyun Park,et al.  RefDNN: a reference drug based neural network for more accurate prediction of anticancer drug resistance , 2020, Scientific Reports.

[6]  Joshua A. Bittker,et al.  Discovering the anticancer potential of non-oncology drugs by systematic viability profiling , 2020, Nature Cancer.

[7]  Andrew R. Leach,et al.  Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens , 2020, bioRxiv.

[8]  M. Sciandrone,et al.  Modeling cancer drug response through drug-specific informative genes , 2019, Scientific Reports.

[9]  A. Lin,et al.  Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials , 2019, Science Translational Medicine.

[10]  G. Lippi,et al.  Statins popularity: A global picture , 2019, British journal of clinical pharmacology.

[11]  D. Pang,et al.  Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells , 2019, Cell Death & Disease.

[12]  Xiaoqi Zheng,et al.  Comprehensive anticancer drug response prediction based on a simple cell line-drug complex network model , 2019, BMC Bioinformatics.

[13]  R. Eckert,et al.  Chk1 inhibition as a novel therapeutic strategy in melanoma , 2018, Oncotarget.

[14]  T. Graeber,et al.  Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. , 2018, Cancer cell.

[15]  Gary Middleton,et al.  Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. , 2018, Cancer discovery.

[16]  Denis Bertrand,et al.  Predicting Cancer Drug Response Using a Recommender System , 2017, bioRxiv.

[17]  Jill P. Mesirov,et al.  Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway , 2017, Nature.

[18]  Angela N. Brooks,et al.  A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles , 2017, Cell.

[19]  Pedro J Ballester,et al.  Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data , 2016, bioRxiv.

[20]  Hristo S. Paskov,et al.  Multitask learning improves prediction of cancer drug sensitivity , 2016, Scientific Reports.

[21]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[22]  K. Akashi,et al.  The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-). , 2016, Cancer research.

[23]  Joshua A. Bittker,et al.  Correlating chemical sensitivity and basal gene expression reveals mechanism of action , 2015, Nature chemical biology.

[24]  Joshua A. Bittker,et al.  Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.

[25]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[26]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[27]  G. Drewes,et al.  Tracking cancer drugs in living cells by thermal profiling of the proteome , 2014, Science.

[28]  K. Yoon,et al.  Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR. , 2014, Experimental cell research.

[29]  J. Hou,et al.  Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells , 2013, Cell Death and Disease.

[30]  Joshua C. Gilbert,et al.  An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules , 2013, Cell.

[31]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[32]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[33]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[34]  J. Boerner,et al.  Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib , 2011, Journal of cellular physiology.

[35]  Wei Zhou,et al.  In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models , 2009, Clinical Cancer Research.

[36]  Anil Potti,et al.  Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors , 2006, BMC Genomics.

[37]  R. Shoemaker The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[38]  Chan Zeng,et al.  Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines , 2006, Molecular Cancer Research.

[39]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Stancu,et al.  Statins: mechanism of action and effects , 2001, Journal of cellular and molecular medicine.

[41]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[42]  Jacob D. Jaffe,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.